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Abstract A paraneoplastic syndrome is occasionally the
first clinical symptom seen with tumours. We report on
two children who initially presented with paraneoplastic
syndromes due to ganglioneuroblastomas: the first with
severe watery diarrhoea caused by a ganglioneuroma
producing vasoactive intestinal peptide, the second with
non-treatable constipation, caused by ganglioneuroma-
produced anti-neuronal nuclear antibodies. Conclusion:
Either severe diarrhoea or chronic constipation may
represent rare paraneoplastic syndromes in ganglioneu-
roblastomas.
Keywords Anti-neuronal nuclear antibodies
Ganglioneuroblastoma Æ Paraneoplastic syndrome
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Abbreviations ANNA anti-neuronal nuclear antibodies
VIP vasoactive intestinal peptide Æ WDHA watery
diarrhoea-hypokalaemia-achlorhydria
Introduction
Paraneoplastic syndromes in children are rare. However,
mature neuroblastomas, i.e. ganglioneuroblastomas, are
known to produce peptides that may cause paraneo-
plastic syndromes, which are mainly neurological, such
as cerebellar encephalopathy [15], opsoclonus-myoclo-
nus [11], and encephalomyelitis/sensory neuronopathy
[17]. Gastrointestinal paraneoplastic syndromes of gan-
glioneuroblastomas have been rarely described.
Within the last 15 years, from 1987 until 2001, in our
institution, 50 children with tumours arising from the
neural crest were diagnosed. Five of them were classified
primarily as ganglioneuroblastoma and four as ganglio-
neuroma.Theremainingcaseswereaneuroblastoma.Two
of the children with a ganglioneuroblastoma presented
exclusively with severe gastrointestinal symptoms, which
were recognised to be rare paraneoplastic syndromes.
Case reports
Case 1
A 19-month-old girl presented with a 4-month history of watery,
non-bloody diarrhoea of large volume and high frequency (8–9
episodes per day), which showed no improvement with dietary
management. Other substantial findings were weight loss, noctur-
nal cramp-like abdominal pain, and meteorism; but no fever. No
other significant medical history, food allergy or unusual ingestion
was reported. On admission, the girl appeared well hydrated and in
relatively good condition, her abdomen was distended and mete-
oristic, no mass palpable, bowel movements were rare. Initial lab-
oratory studies showed normal haematological parameters, CRP,
serum sodium and chloride, whereas potassium was 2.1 mmol/l.
Investigations for coeliac disease, cow’s milk allergy, as well as for
intestinal infections were negative. A colon contrast enema in
search of a tumour was inconspicuous. However, a CT scan re-
vealed a presacral mass. A percutaneous biopsy of the tumour
showed histological features consistent with a ganglioneuroblas-
toma. Investigation of the N-myc gene amplification was negative.
The working hypothesis thereafter was that the diarrhoea might be
a sign of a paraneoplastic syndrome due to vasoactive intestinal
polypeptide (VIP) produced by the tumour. Further laboratory
investigations confirmed this hypothesis: The level of VIP was
significantly elevated (960 pmol/l, normal <25 pmol/l), as were
those of vanillylmandelic acid, urinary homovanillic acid, chro-
mogranin-B-sequence and neuron-specific enolase antigen, as well
as the neuropeptides somatostatin, peptide histidine methionine,
and gastrin. MIBG scintigraphy did not reveal metastases. Because
of a primarily non-resectable unilateral tumour passing the midline,
Eur J Pediatr (2003) 162: 511–513
DOI 10.1007/s00431-003-1212-0
Barbara Wildhaber Æ Felix Niggli Æ Eva Bergsträsser
Thomas Stallmach Æ Peter Sacher
B. Wildhaber (&) Æ P. Sacher





F. Niggli Æ E. Bergsträsser
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a preoperative chemotherapy according to the German NB-97
study protocol, standard risk, was initiated for this stage 3 tumour.
But despite chemotherapy, the intense diarrhoea persisted and
hypokalaemic episodes recurred. Therefore, laparotomy and
resection of the tumour was performed 7 weeks after diagnosis
(after two blocks of chemotherapy). The histological examination
revealed a ganglioneuroblastoma with 70% neuroblastoma cells.
VIP, but not somatostatin, tested positive immunohistochemically
in the differentiated parts of the tumour. No additional chemo-
therapy was initiated. Peri-operatively, the patient showed high
blood pressures (around 135/95 mmHg) requiring medical treat-
ment. The early post-operative management was complicated by
lung oedema and a thrombosis of the external iliac vein, which were
treated conservatively with furosemide and agents for anticoagu-
lation. Following a second operation for ileus due to a post-oper-
ative intussusception of the small bowel, the girl showed regular
bowel movements with normal consistency, frequency, and volume.
Potassium levels remained stable within normal limits. Six days
post-operatively, values of VIP were within normal range
(18 pmol/l). The patient has up to now remained free of disease
(2 years post-surgery).
Case 2
A previously healthy 14-year-old girl presented with severe con-
stipation as the sole clinical symptom lasting several weeks. Work-
up, including an abdominal ultrasound and CTscan, revealed a
right-sided 5·4·5 cm suprarenal mass. Vanillylmandelic acid val-
ues were normal. However, MIBG scintigraphy showed an
abnormal uptake of radionucleids into the left suprarenal region.
The tumour was completely resected by laparotomy. Histology
confirmed a para-adrenal ganglioneuroblastoma. The blastoma
(5% of the total mass of the tumour) was located in the centre of
the tumour and therefore was considered to have been resected
completely. Simultaneous biopsies of the rectal mucosa showed a
normal histology. No further treatment was initiated. No consti-
pation was evident for several weeks, after which complaints re-
curred. Eight months after the first operation, locally a recurrent
tumour was found on a regular follow-up CT scan. A second
laparotomy with resection of the local tumour relapse was per-
formed. Histology again confirmed a ganglioneuroblastoma.
Thereafter, the constipation was initially sufficiently controlled by
enemas and laxatives. Due to exacerbation of the painful consti-
pation with gross dilatation of the colon and failure of any con-
servative treatment, a third laparotomy became necessary and a
caecostomy for antegrade bowel wash-outs was placed 8 months
after the second laparotomy. Intra-operative direct observation
showed a complete lack of propulsive motility within the large
bowel. A full-thickness biopsy of the colon revealed chronic
inflammation of the myenteric plexus with destruction of the gan-
glion cells, but with an intact submucous plexus (Fig. 1). Control of
constipation was achieved by regular antegrade bowel washout
enemas. Two weeks later, the girl presented with ileus; however, the
immediate laparotomy did not reveal any mechanical cause.
Therefore, an ileostomy as well as a jejunal feeding enterostomy
were placed. At that time, the full thickness biopsy of the small
bowel failed to show any ganglion cells within the myenteric plexus;
inflammation had subsided. These combined findings suggested an
immunogenic process initiating ganglionitis with subsequent
destruction of ganglion cells. Assay of anti-neuronal nuclear anti-
bodies (ANNA) revealed elevated levels with a titre of 1:1280
(normal <1:40). A tentative therapy with glucocorticoids was in-
effective, and the high titres of ANNA persisted. 1.5 years after the
first laparotomy, a second relapse of the tumour was detected on a
follow-up CT scan. Chemotherapy as well as radiotherapy were
unsuccessful. A fifth laparotomy with resection of multiple tumour
relapses was performed. Histology confirmed vital gang-
lioneuroblastoma, necrosis, and calcifications in the specimen.
Simultaneously, a total colectomy anticipating an ileo-rectal pull-
through later on was performed. Extensive investigation of the
colon specimen failed to demonstrate one single ganglion cell
within the myenteric plexus, whereas the submucous plexus ap-
peared normal. The ileostomy was left in place. The patient died 18
months later due to tumour progression.
Discussion
Mature neuroblastomas, i.e. ganglioneuroblastomas, are
known to produce substances that cause paraneoplastic
syndromes [5]. A paraneoplastic syndrome may be de-
fined as a dysfunction of organ systems caused by the
remote humoral effects of a tumour and not by local
effects or metastases.
Secretory diarrhoea and severe hypokalaemia are
part of the watery diarrhoea, hypokalaemia and
achlorhydria (WDHA) syndrome which was first de-
scribed by Verner and Morrison in 1958 [18] in associ-
ation with islet cell tumours of the pancreas in an adult.
At that time, the aetiological agent was not known.
Today, there is evidence that these symptoms are related
to VIP production in tumour cells. Histologically, VIP-
producing tumours can be divided into two groups:
pancreatic endocrine tumours and neurogenic tumours,
including ganglioneuroblastomas, ganglioneuromas,
and pheochromocytomas. These tumours most fre-
quently occur in the adrenal glands or retroperitoneum.
VIP is the most useful laboratory finding enabling the
detection of hormone-producing ganglioneuroblasto-
mas. In addition, 50% of patients may show elevated
levels of urinary catecholamines [12] and elevation of
various neuropeptides [5]. VIP was first isolated in 1970
by Said and Mutt [13] from porcine gut, and they
demonstrated that VIP stimulates intestinal secretions.
It is known that VIP has effects on the cardiovascular,
respiratory, and gastrointestinal systems. It resembles
secretin in that it stimulates secretion of alkaline pan-
creatic juice. Similar to glucagon, it stimulates lipolysis
and glycogenolysis. Furthermore, it relaxes smooth
muscle leading to decreased intestinal movements, as
clinically observed in our patient. VIP inhibits histamine
Fig. 1 Full thickness biopsy of the colon. Lymphocytes and plasma
cells around altered ganglion cells within the myenteric plexus
(synaptophysin x800)
512
and pentagastrin-stimulated acid secretion in the stom-
ach and is, in addition, a potent stimulator of the
adenylate cyclase production by the intestinal mucosal
cells, resulting in net secretion of water and electrolytes.
Somatostatin may be used for medical treatment of the
WDHA syndrome. Somatostatin inhibits gastrointesti-
nal secretion and in some cases may prove helpful [3].
Other treatments include steroids, cholestyramine or
loperamide. Recommended medical treatment of VIP-
producing ganglioneuroblastomas requires surgical re-
moval of the tumour. VIP levels are preferably used
post-operatively to monitor tumour recurrence.
Severe constipation in an adolescent girl is not
uncommon, and the differential diagnosis is extensive.
Aetiologies can range from dietary and psychosocial
disturbances, to metabolic diseases, gastrointestinal
abnormalities, intrapelvic tumours and neuropathic rec-
tum. Intestinal pseudo-obstruction as a paraneoplastic
syndrome is rare and has mainly been reported in pa-
tients with small cell lung cancers [8, 9, 10], but only
seldom in association with other malignant tumours [6, 7,
8], and not yet in connection with a ganglioneuroblas-
toma or neuroblastoma. Cancer patients with paraneo-
plastic disease show significantly higher titres of ANNA
compared to those without the syndrome. In our second
case, the intestinal pseudo-obstruction was due to a
destruction of ganglion cells of the myenteric plexus
caused by high levels of ANNA. The immunoglobin G
ANNA, or anti-Hu, is thought to be part of an immune
response originally directed against tumour antigens. In
our patient, there was strong evidence that the immu-
nological process leading to auto-antibodies was initiated
within the ganglioneuroblastoma. ANNA react with
antigens shared by tumour cells and neurons, including
the myenteric plexus [2]. Intestinal pseudo-obstruction
due to acquired aganglionosis by auto-antibodies has
been described in young adults without neoplasia or
other neuronal involvement [16]. The typical paraneo-
plastic syndrome associated with elevated levels of
ANNA is a sensoric neuronopathy with paresthesia and
stiffness, which was also observed in our patient, al-
though it was not one of the leading symptoms. Intestinal
pseudo-obstruction is a much less common presentation
of the syndrome. It may be found isolated, or as a part of
other autonomic dysfunctions [1]. Interestingly, gan-
glionitis with subsequent destruction of ganglion cells
does not affect cells of the submucous plexus. Therefore,
mucosal biopsies are not sufficient in detecting auto-im-
mune ganglionitis. In our patient it remains unknown
whether the destruction of the ganglion cells in the my-
enteric plexus was already present when rectal mucosal
biopsies were performed during the initial operation (the
histopathological findings have recently been discussed
in detail by Schobinger-Clément et al. [14]). In cases of
ganglioneuroblastoma with intestinal pseudo-obstruc-
tion, serum testing for auto-antibodies will reveal the
cause of the paraneoplastic disease. Presently, the main
therapeutic option for this auto-immune destruction of
ganglion cells is surgical removal of the tumour. Steroids
and immunoglobulins have been used in cases with ele-
vated ANNA levels and various neurological symptoms,
but with inconsistent benefit [4]. ANNA levels can be
used for monitoring and detection of tumour recurrence.
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